It's also approved for reducing cardiovascular event risk in adults with cardiovascular disease who are overweight or obese
Based on our findings and current understanding of IIH pathophysiology, optimal candidates include patients with inadequate response to first-line treatments and those with significant metabolic dysfunction [4, 5, 14, 18]
In clinical studies, the average weight loss was 15% and 20% with 77% of patients seeing sustained results for 2 years* *In a 68- and 72-week clinical trial studying Semaglutide in patients without diabetes and with BMI 30, or BMI 27 with a weight-related condition, the average weight loss was 15% and 20%, when paired with diet and exercise changes (compared to 2.4% and 3.1%, respectively, with diet and exercise alone)
A patient losing weight steadily at 1.0 mg weekly has no clinical reason to escalate
The safest approach: know which syringe type your chart references
Date, dose, injection site, any side effects